Atherosclerosis and CV Risk in Lupus
Ground-breaking trials presented at the 2018 European Lupus Society meeting demonstrate that inexpensive office-based tools can predict impending cardiovascular disease in patients with lupus.
References1. Hermansen MLF, Faurschou M, Jacobsen S. Beta2-microglobulin (B2MG) plasma levels associate with markers of atherosclerosis in patients with systemic lupus erythematosus (SLE). Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.2. Parvu M, Coman S, Tilinca M, Voidazan S. A simple method to evidence subclinical atherosclerosis in patients with systemic lupus erythematosus. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.3. Bakshi J, Isenberg D, Rahman A. Increased risk of cardiovascular disease in patients with SLE who have asymptomatic plaque on vascular ultrasound â a five-year follow-up study. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.
